Hsp27 as a therapeutic target in cancers

Current Drug Targets

Volumn 15, Issue 4, 2014, Pages 423-431

  Acunzo, Julie ^a,b,c   Andrieu, Claudia ^a,b,c   Baylot, Virginie ^a,b,c   So, Alan ^d   Rocchi, Palma ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CNRS   (France)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer; Heat shock protein Hsp27; Protein inhibition; Targeted therapy

Indexed keywords

APATORSEN; APOPTOSIS SIGNAL REGULATING KINASE 1; CHAPERONE; CISPLATIN; DAXX PROTEIN; DOXORUBICIN; GELATINASE A; GELATINASE B; GEMCITABINE; HEAT SHOCK PROTEIN 22; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN B10; HEAT SHOCK PROTEIN B11; HEAT SHOCK PROTEIN B2; HEAT SHOCK PROTEIN B4; HEAT SHOCK PROTEIN B5; HEAT SHOCK PROTEIN B7; HEAT SHOCK PROTEIN B8; HEAT SHOCK PROTEIN B9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RP 101; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CYTOSKELETON; HUMAN; IMMUNOTOXICITY; MUTAGENESIS; NEOPLASM; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS;

EID: 84896348569     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113146660230     Document Type: Review

References (127)

1. Hickey ED, Weber LA. Modulation of heat-shock polypeptide synthesis in HeLa cells during hyperthermia and recovery. Biochemistry 1982; 21(7): 1513-21.
2. Kappe G, Franck E, Verschuure P, Boelens WC, Leunissen JA, de Jong WW. The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones 2003; 8(1): 53-61.
3. Stock AD, Spallone PA, Dennis TR, et al. Heat shock protein 27 gene: chromosomal and molecular location and relationship to Williams syndrome. Am J Med Genet A 2003; 120A(3): 320-5.
4. Haslbeck M. sHsps and their role in the chaperone network. Cell Mol Life Sci 2002; 59(10): 1649-57.
5. Nakamoto H, Vigh L. The small heat shock proteins and their clients. Cell Mol Life Sci 2007; 64(3): 294-306.
6. Ehrnsperger M, Graber S, Gaestel M, Buchner J. Binding of nonnative protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation. EMBO J 1997 15; 16(2): 221-9.
7. Gusev NB, Bogatcheva NV, Marston SB. Structure and properties of small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry (Mosc) 2002; 67(5): 511-9.
8. Kappe G, Boelens WC, de Jong WW. Why proteins without an alpha-crystallin domain should not be included in the human small heat shock protein family HSPB. Cell Stress Chaperones 2010; 15(4): 457-61.
9. Lelj-Garolla B, Mauk AG. Self-association of a small heat shock protein. J Mol Biol 2005; 345(3): 631-42.
10. Kim KK, Kim R, Kim SH. Crystal structure of a small heat-shock protein. Nature 1998; 394(6693): 595-9.
11. van Montfort RL, Basha E, Friedrich KL, Slingsby C, Vierling E. Crystal structure and assembly of a eukaryotic small heat shock protein. Nat Struct Biol 2001; 8(12): 1025-30.
12. Bova MP, McHaourab HS, Han Y, Fung BK. Subunit exchange of small heat shock proteins. Analysis of oligomer formation of alphaA-crystallin and Hsp27 by fluorescence resonance energy transfer and site-directed truncations. J Biol Chem 2000; 275(2): 1035-42.
13. Hilario E, Martin FJ, Bertolini MC, Fan L. Crystal structures of Xanthomonas small heat shock protein provide a structural basis for an active molecular chaperone oligomer. J Mol Biol 2011; 408(1): 74-86.
14. Stamler R, Kappe G, Boelens W, Slingsby C. Wrapping the alphacrystallin domain fold in a chaperone assembly. J Mol Biol 2005; 353(1): 68-79.
15. Knapinska AM, Gratacos FM, Krause CD, et al. Chaperone Hsp27 modulates AUF1 proteolysis and AU-rich element-mediated mRNA degradation. Mol Cell Biol 2011; 31(7): 1419-31.
16. Koteiche HA, McHaourab HS. The determinants of the oligomeric structure in Hsp16.5 are encoded in the alpha-crystallin domain. FEBS Lett 2002; 519(1-3): 16-22.
17. Ghosh JG, Houck SA, Clark JI. Interactive sequences in the molecular chaperone, human alphaB crystallin modulate the fibrillation of amyloidogenic proteins. Int J Biochem Cell Biol 2008; 40(5): 954-67.
18. Lambert H, Charette SJ, Bernier AF, Guimond A, Landry J. HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus. J Biol Chem 1999; 274(14): 9378-85.
19. Hayes D, Napoli V, Mazurkie A, Stafford WF, Graceffa P. Phosphorylation dependence of hsp27 multimeric size and molecular chaperone function. J Biol Chem 2009; 284(28): 18801-7.
20. Rogalla T, Ehrnsperger M, Preville X, et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 1999; 274(27): 18947-56.
21. Haley DA, Bova MP, Huang QL, McHaourab HS, Stewart PL. Small heat-shock protein structures reveal a continuum from symmetric to variable assemblies. J Mol Biol 2000; 298(2): 261-72.
22. Nagaraj RH, Oya-Ito T, Padayatti PS, et al. Enhancement of chaperone function of alpha-crystallin by methylglyoxal modification. Biochemistry 2003; 42(36): 10746-55.
23. Oya-Ito T, Liu BF, Nagaraj RH. Effect of methylglyoxal modification and phosphorylation on the chaperone and antiapoptotic properties of heat shock protein 27. J Cell Biochem 2006; 99(1): 279-91.
24. Sakamoto H, Mashima T, Yamamoto K, Tsuruo T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J Biol Chem 2002; 277(48): 45770-5.
25. van Heijst JW, Niessen HW, Musters RJ, van Hinsbergh VW, Hoekman K, Schalkwijk CG. Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis. Cancer Lett 2006; 241(2): 309-19.
26. Zavialov AV, Gaestel M, Korpela T, Zav'yalov VP. Thiol/disulfide exchange between small heat shock protein 25 and glutathione. Biochim Biophys Acta 1998; 1388(1): 123-32.
27. Eaton P, Fuller W, Shattock MJ. S-thiolation of HSP27 regulates its multimeric aggregate size independently of phosphorylation. J Biol Chem 2002; 277(24): 21189-96.
28. Butt E, Immler D, Meyer HE, Kotlyarov A, Laass K, Gaestel M. Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J Biol Chem 2001; 276(10): 7108-13.
29. Landry J, Lambert H, Zhou M, et al. Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogenactivated kinases that recognize the same amino acid motif as S6 kinase II. J Biol Chem 1992; 267(2): 794-803.
30. Kato K, Hasegawa K, Goto S, Inaguma Y. Dissociation as a result of phosphorylation of an aggregated form of the small stress protein, hsp27. J Biol Chem 1994; 269(15): 11274-8.
31. Bruey JM, Paul C, Fromentin A, et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000; 19(42): 4855-63.
32. Bukach OV, Glukhova AE, Seit-Nebi AS, Gusev NB. Heterooligomeric complexes formed by human small heat shock proteins HspB1 (Hsp27) and HspB6 (Hsp20). Biochim Biophys Acta 2009; 1794(3): 486-95.
33. Sun X, Fontaine JM, Rest JS, Shelden EA, Welsh MJ, Benndorf R. Interaction of human HSP22 (HSPB8) with other small heat shock proteins. J Biol Chem 2004; 279(4): 2394-402.
34. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. Regulation of actin filament dynamics by p38 map kinasemediated phosphorylation of heat shock protein 27. J Cell Sci 1997; 110 (Pt 3): 357-68.
35. Lavoie JN, Lambert H, Hickey E, Weber LA, Landry J. Modulation of cellular thermoresistance and actin filament stability accompanies phosphorylation-induced changes in the oligomeric structure of heat shock protein 27. Mol Cell Biol 1995; 15(1): 505-16.
36. Charette SJ, Lavoie JN, Lambert H, Landry J. Inhibition of Daxxmediated apoptosis by heat shock protein 27. Mol Cell Biol 2000; 20(20): 7602-12.
37. Parcellier A, Brunet M, Schmitt E, et al. HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. FASEB J 2006; 20(8): 1179-81.
38. Parcellier A, Schmitt E, Gurbuxani S, et al. HSP27 is a ubiquitinbinding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol 2003; 23(16): 5790-802.
39. Lelj-Garolla B, Mauk AG. Self-association and chaperone activity of Hsp27 are thermally activated. J Biol Chem 2006; 281(12): 8169-74.
40. Shashidharamurthy R, Koteiche HA, Dong J, McHaourab HS. Mechanism of chaperone function in small heat shock proteins: dissociation of the HSP27 oligomer is required for recognition and binding of destabilized T4 lysozyme. J Biol Chem 2005; 280(7): 5281-9.
41. Barutta F, Pinach S, Giunti S, et al. Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295(6): F1817-24.
42. Berkowitz P, Chua M, Liu Z, Diaz LA, Rubenstein DS. Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin. Am J Pathol 2008; 173(6): 1628-36.
43. Berkowitz P, Diaz LA, Hall RP, Rubenstein DS. Induction of p38MAPK and HSP27 phosphorylation in pemphigus patient skin. J Invest Dermatol 2008; 128(3): 738-40.
44. Vidyasagar A, Reese S, Acun Z, Hullett D, Djamali A. HSP27 is involved in the pathogenesis of kidney tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2008; 295(3): F707-16.
45. Schlapbach A, Feifel R, Hawtin S, et al. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity. Bioorg Med Chem Lett 2008 1; 18(23): 6142-6.
46. Mikalsen T, Gerits N, Moens U. Inhibitors of signal transduction protein kinases as targets for cancer therapy. Biotechnol Annu Rev 2006; 12: 153-223.
47. Franck E, Madsen O, van Rheede T, Ricard G, Huynen MA, de Jong WW. Evolutionary diversity of vertebrate small heat shock proteins. J Mol Evol 2004; 59(6): 792-805.
48. Kato K, Shinohara H, Goto S, Inaguma Y, Morishita R, Asano T. Copurification of small heat shock protein with alpha B crystallin from human skeletal muscle. J Biol Chem 1992; 267(11): 7718-25.
49. Wehmeyer N, Vierling E. The expression of small heat shock proteins in seeds responds to discrete developmental signals and suggests a general protective role in desiccation tolerance. Plant Physiol 2000; 122(4): 1099-108.
50. Geiger R, Sharma HS, Mooi WJ, Berger RM. Pulmonary vascular remodeling in congenital heart disease: enhanced expression of heat shock proteins. Indian J Biochem Biophys 2009; 46(6): 482-90.
51. Lutsch G, Vetter R, Offhauss U, et al. Abundance and location of the small heat shock proteins HSP25 and alphaB-crystallin in rat and human heart. Circulation 1997; 96(10): 3466-76.
52. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10(2): 86-103.
53. Krueger-Naug AM, Emsley JG, Myers TL, Currie RW, Clarke DB. Administration of brain-derived neurotrophic factor suppresses the expression of heat shock protein 27 in rat retinal ganglion cells following axotomy. Neuroscience 2003; 116(1): 49-58.
54. Bechtold DA, Brown IR. Induction of Hsp27 and Hsp32 stress proteins and vimentin in glial cells of the rat hippocampus following hyperthermia. Neurochem Res 2003; 28(8): 1163-73.
55. Gaestel M, Gotthardt R, Muller T. Structure and organisation of a murine gene encoding small heat-shock protein Hsp25. Gene 1993; 128(2): 279-83.
56. Mosser DD, Kotzbauer PT, Sarge KD, Morimoto RI. In vitro activation of heat shock transcription factor DNA-binding by calcium and biochemical conditions that affect protein conformation. Proc Natl Acad Sci USA 1990; 87(10): 3748-52.
57. Fuqua SA, Blum-Salingaros M, McGuire WL. Induction of the estrogen-regulated "24K" protein by heat shock. Cancer Res 1989; 49(15): 4126-9.
58. Banerjee S, Lin CF, Skinner KA, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res 2011; 71(2): 318-27.
59. Laudanski K, De A, Miller-Graziano C. Exogenous heat shock protein 27 uniquely blocks differentiation of monocytes to dendritic cells. Eur J Immunol 2007; 37(10): 2812-24.
60. Periard JD, Ruell P, Caillaud C, Thompson MW. Plasma Hsp72 (HSPA1A) and Hsp27 (HSPB1) expression under heat stress: influence of exercise intensity. Cell Stress Chaperones 2012 Jan 6.
61. Markov DI, Pivovarova AV, Chernik IS, Gusev NB, Levitsky DI. Small heat shock protein Hsp27 protects myosin S1 from heatinduced aggregation, but not from thermal denaturation and ATPase inactivation. FEBS Lett 2008; 582(10): 1407-12.
62. Pivovarova AV, Chebotareva NA, Chernik IS, Gusev NB, Levitsky DI. Small heat shock protein Hsp27 prevents heat-induced aggregation of F-actin by forming soluble complexes with denatured actin. FEBS J 2007; 274(22): 5937-48.
63. McHaourab HS, Godar JA, Stewart PL. Structure and mechanism of protein stability sensors: chaperone activity of small heat shock proteins. Biochemistry 2009; 48(18): 3828-37.
64. Mathew SS, Della Selva MP, Burch AD. Modification and reorganization of the cytoprotective cellular chaperone Hsp27 during herpes simplex virus type 1 infection. J Virol 2009; 83(18): 9304-12.
65. Kostenko S, Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 2009; 66(20): 3289-307.
66. Arrigo AP. The cellular "networking" of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis. Adv Exp Med Biol 2007; 594: 14-26.
67. Garrido C, Ottavi P, Fromentin A, et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res 1997 Jul 1; 57(13): 2661-7.
68. Paul C, Manero F, Gonin S, Kretz-Remy C, Virot S, Arrigo AP. Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 2002; 22(3): 816-34.
69. Pandey P, Farber R, Nakazawa A, et al. Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 2000; 19(16): 1975-81.
70. Mehlen P, Hickey E, Weber LA, Arrigo AP. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generates a protection against TNFalpha in NIH-3T3-ras cells. Biochem Biophys Res Commun 1997; 241(1): 187-92.
71. Preville X, Salvemini F, Giraud S, et al. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp Cell Res 1999; 247(1): 61-78.
72. Koh TJ, Escobedo J. Cytoskeletal disruption and small heat shock protein translocation immediately after lengthening contractions. Am J Physiol Cell Physiol 2004; 286(3): C713-22.
73. Ferns G, Shams S, Shafi S. Heat shock protein 27: its potential role in vascular disease. Int J Exp Pathol 2006; 87(4): 253-74.
74. Mounier N, Arrigo AP. Actin cytoskeleton and small heat shock proteins: how do they interact? Cell Stress Chaperones 2002; 7(2): 167-76.
75. An SS, Fabry B, Mellema M, et al. Role of heat shock protein 27 in cytoskeletal remodeling of the airway smooth muscle cell. J Appl Physiol 2004; 96(5): 1701-13.
76. Ibitayo AI, Sladick J, Tuteja S, et al. HSP27 in signal transduction and association with contractile proteins in smooth muscle cells. Am J Physiol 1999; 277(2 Pt 1): G445-54.
77. Somara S, Bitar KN. Tropomyosin interacts with phosphorylated HSP27 in agonist-induced contraction of smooth muscle. Am J Physiol Cell Physiol 2004; 286(6): C1290-301.
78. Jia Y, Wu SL, Isenberg JS, et al. Thiolutin inhibits endothelial cell adhesion by perturbing Hsp27 interactions with components of the actin and intermediate filament cytoskeleton. Cell Stress Chaperones 2010; 15(2): 165-81.
79. Lee JS, Zhang MH, Yun EK, et al. Heat shock protein 27 interacts with vimentin and prevents insolubilization of vimentin subunits induced by cadmium. Exp Mol Med 2005; 37(5): 427-35.
80. Bausero MA, Bharti A, Page DT, et al. Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell. Tumour Biol 2006; 27(1): 17-26.
81. Evans IM, Britton G, Zachary IC. Vascular endothelial growth factor induces heat shock protein (HSP) 27 serine 82 phosphorylation and endothelial tubulogenesis via protein kinase D and independent of p38 kinase. Cell Signal 2008; 20(7): 1375-84.
82. Incorvaia L, Badalamenti G, Rini G, et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res 2007; 27(3B): 1519-25.
83. Konishi H, Matsuzaki H, Tanaka M, et al. Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association with heat shock protein Hsp27. FEBS Lett 1997; 410(2-3): 493-8.
84. Rane MJ, Pan Y, Singh S, et al. Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 2003; 278(30): 27828-35.
85. Havasi A, Li Z, Wang Z, et al. Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 2008; 283(18): 12305-13.
86. Stetler RA, Gao Y, Signore AP, Cao G, Chen J. HSP27: mechanisms of cellular protection against neuronal injury. Curr Mol Med 2009; 9(7): 863-72.
87. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol 2000; 2(9): 645-52.
88. Concannon CG, Orrenius S, Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr 2001; 9(4-5): 195-201.
89. Chauhan D, Li G, Hideshima T, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003; 102(9): 3379-86.
90. Zoubeidi A, Zardan A, Wiedmann RM, et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010; 70(6): 2307-17.
91. Arya R, Mallik M, Lakhotia SC. Heat shock genes-integrating cell survival and death. J Biosci 2007; 32(3): 595-610.
92. Charette SJ, Landry J. The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis. Ann N Y Acad Sci 2000; 926: 126-31.
93. Arts HJ, Hollema H, Lemstra W, et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer 1999; 84(3): 234-8.
94. Bostwick DG. Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol Urol 2000; 4(3): 101-6; discussion 7.
95. Malusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res 2001; 21(2A): 1015-21.
96. Garrido C, Fromentin A, Bonnotte B, et al. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res 1998; 58(23): 5495-9.
97. Lemieux P, Oesterreich S, Lawrence JA, et al. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 1997; 17(3): 113-23.
98. Choi DH, Ha JS, Lee WH, et al. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett 2007; 581(8): 1649-56.
99. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormonerefractory prostate cancer. Cancer Res 2004; 64(18): 6595-602.
100. Zhang Y, Shen X. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 2007; 13(10): 2855-64.
101. Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anticancer Res 2006; 26(2B): 1583-7.
102. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60(24): 7099-105.
103. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65(23): 11083-93.
104. Hoang AT, Huang J, Rudra-Ganguly N, et al. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 2000; 156(3): 857-64.
105. Song H, Ethier SP, Dziubinski ML, Lin J. Stat3 modulates heat shock 27kDa protein expression in breast epithelial cells. Biochem Biophys Res Commun 2004; 314(1): 143-50.
106. Fuqua SA, Benedix MG, Krieg S, Weng CN, Chamness GC, Oesterreich S. Constitutive overexpression of the 27,000 dalton heat shock protein in late passage human breast cancer cells. Breast Cancer Res Treat 1994; 32(2): 177-86.
107. Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 2012; 44(10): 1646-56.
108. Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int 2008; 102(5): 610-6.
109. Hadchity E, Aloy MT, Paulin C, et al. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. Mol Ther 2009; 17(8): 1387-94.
110. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007; 6(1): 299-308.
111. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806-11.
112. Liu X, Liu C, Laurini E, et al. Efficient Delivery of Sticky siRNA and Potent Gene Silencing in a Prostate Cancer Model Using a Generation 5 Triethanolamine-Core PAMAM Dendrimer. Mol Pharm 2012; 9(3): 470-81.
113. Liu X, Wu J, Yammine M, et al. Structurally flexible triethanolamine core PAMAM dendrimers are effective nanovectors for DNA transfection in vitro and in vivo to the mouse thymus. Bioconjug Chem 2011; 22(12): 2461-73.
114. Liu XX, Rocchi P, Qu FQ, et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem 2009; 4(8): 1302-10.
115. Kaur P, Nagaraja GM, Asea A. Combined lentiviral and RNAi technologies for the delivery and permanent silencing of the hsp25 gene. Methods Mol Biol 2011; 787: 121-36.
116. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv 2011; 29(4): 402-17.
117. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011; 10(7): 521-35.
118. Xia Y, Liu Y, Rocchi P, et al. Targeting heat shock factor 1 with a triazole nucleoside analog to elicit potent anticancer activity on drug-resistant pancreatic cancer. Cancer Lett 2012; 318(2): 145-53.
119. Xia Y, Liu Y, Wan J, et al. Novel triazole ribonucleoside downregulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem 2009; 52(19): 6083-96.
120. Xia Y, Rocchi P, Iovanna JL, Peng L. Targeting heat shock response pathways to treat pancreatic cancer. Drug Discov Today 2012; 17(1-2): 35-43.
121. Heinrich JC, Tuukkanen A, Schroeder M, Fahrig T, Fahrig R. RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol 2011; 137(9): 1349-61.
122. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett 2013; 23(7): 1923-8.
123. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclindependent kinase 2. Nature 1996; 380(6574): 548-50.
124. Geyer CR, Brent R. Selection of genetic agents from random peptide aptamer expression libraries. Methods Enzymol 2000; 328: 171-208.
125. Chattopadhyay A, Tate SA, Beswick RW, Wagner SD, Ko Ferrigno P. A peptide aptamer to antagonize BCL-6 function. Oncogene 2006; 25(15): 2223-33.
126. Nouvion AL, Thibaut J, Lohez OD, et al. Modulation of Nr-13 antideath activity by peptide aptamers. Oncogene 2007; 26(5): 701-10.
127. Gibert B, Hadchity E, Czekalla A, et al. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene 2011; 30(34): 3672-81.